Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest multiple sclerosis Stories

2013-04-19 18:02:46

A major Nordic research project involving researchers from the University of Copenhagen has, for the first time ever, mapped the use of alternative treatment among multiple sclerosis patients - knowledge which is important for patients with chronic disease and the way in which society meets them. People with multiple sclerosis (MS) often use alternative treatments such as dietary supplements, acupuncture and herbal medicine to facilitate their lives with this chronic disease. This is the...

2013-04-16 08:28:33

-- 65 new grants and fellowships part of 2013 investment of over $47 million in cutting-edge research projects moving us closer to a world free of MS NEW YORK, April 16, 2013 /PRNewswire-USNewswire/ -- The National Multiple Sclerosis Society has committed another $18 million to support up to 65 new MS research projects. These new awards are part of a comprehensive research strategy aimed at stopping MS, restoring function that has been lost, and ending the disease forever. (Logo:...

2013-04-10 23:02:54

According to Ironclad Integrity Ltd MS natural treatments have become all the rage lately as these promise effective results, no side-effects and lower health care bills. The company has released via http://www.SclerosisTreatment.com reviews and price analysis for the most popular MS alternative therapies. Denver, Colorado (PRWEB) April 10, 2013 Health organizations estimate there are about 400,000 Multiple Sclerosis patients in the United States today, but that number is certainly higher...

2013-04-10 08:30:35

- Adds to Earlier Data Demonstrating Potential to Restore Myelin in MS Patients - SEATTLE, April 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled...

2013-04-09 12:29:09

BROOMFIELD, Colo., April 9, 2013 /PRNewswire/ -- Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today a study in collaboration with the University of Miami Miller School of Medicine. The study will examine the effects of Accera's medical food, Axona, on cognitive impairment in patients with multiple sclerosis (MS). Axona is a...

2013-04-08 08:31:12

An Increased Effect in Preventing Sustained Disability Progression is One of the Greatest Unmet Needs in RR-MS, According to a New Report from Decision Resources BURLINGTON, Mass., April 8, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. neurologists indicated that they would prescribe Biogen Idec's Tecfidera to 20 percent of their patients with relapsing-remitting...

2013-04-05 08:23:02

People living with multiple sclerosis (MS) and MS experts available to speak about the importance of NIH funding for life-changing MS research WASHINGTON, April 5, 2013 /PRNewswire-USNewswire/ -- On April 8 at 11 a.m., thousands of people will gather on the Carnegie Library grounds to participate in the Rally for Medical Research to raise awareness of the critical need to make funding for the National Institutes of Health (NIH) a priority. The National MS Society and nearly 200 other...

2013-04-04 16:23:46

-- Patent Expands Company's Patent Portfolio to Include Combination with Number One Selling Multiple Sclerosis Drug -- ROCKVILLE, Md., April 4, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,372,826 entitled, Estriol Therapy for Multiple Sclerosis and Other Autoimmune...

2013-04-03 23:03:21

Oral disease-modifying drugs are recent additions to the multiple sclerosis market. New York, NY (PRWEB) April 03, 2013 Multiple sclerosis patients who are taking oral disease-modifying drugs (DMD) are more optimistic about their future expectations for their disease than patients who are taking non-oral DMDs, according to new research from Kantar Health, a leading global healthcare advisory firm. More than 950 MS patients were asked to predict whether they expected their disease to...

2013-04-03 23:03:05

Dr. Saud A. Sadiq to Discuss Cellular Therapy for MS at the Second International Adult Stem Cell Conference: Regenerative Medicine — A Fundamental Shift in Science and Culture. New York, NY (PRWEB) April 03, 2013 The Tisch MS Research Center of New York announced today that Dr. Saud A. Sadiq has accepted an invitation to participate in the Second International Adult Stem Cell Conference: Regenerative Medicine - A Fundamental Shift in Science and Culture to be held within the Vatican,...